To obtain insight into the structure−activity
relationships of new antitumor active platinum compounds the
X-ray
structure of the antitumor active Pt compound
[Pt(bmic)Cl2] (bmic =
bis-(N-methylimidazol-2-yl)carbinol)
(1)
and its interaction with short DNA fragments has been investigated
using NMR spectroscopy. For comparison
also the structurally related compound
[Pt(bmi)Cl2] (bmi =
N
1,N
1‘-dimethyl-2,2‘-biimidazole)
(2), which is not
antitumor active, has been studied. The structure of the compound
[Pt(bmic)Cl2] (1) was characterized
by single-crystal X-ray structure determination. Compound 1
crystallizes in the monoclinic space group
P21/n, with a
=
10.055(3) Å, b = 11.802(3) Å, c =
10.620(3) Å, β = 103.78(2)°, V =
1224.0(6) Å3 and Z = 4.
Convergence
was reached at wR2 = 0.1148 (all data) and R1 = 0.0476
(I > 2 (I)) for 2433 independent reflections and
156
adjustable parameters. The platinum atom is coordinated by two
nitrogen and two chlorine atoms, resulting in
a square planar PtN2Cl2 coordination
sphere. The two best least-squares planes through the two
imidazole rings
of the bmic ligand show a dihedral angle of 30.6°. The in
vitro and in vivo antitumor activity of 1 is
significant
whereas for compound 2 no antitumor activity could be
detected. In P388 mice leukemia an increase of
lifespan
of 56% was found for complex 1. The antitumor active
Pt compound [Pt(bmic)Cl2] binds to G bases in a
similar
fashion as cisplatin with a clear preference for N7. In reaction
with d(GpG) two stereoisomers are formed, due
to the unsymmetric bmic complex and the chiral d(GpG) molecule.
Stereoisomer A, i.e. the isomer with the
OH
group of the bmic and the O6 of the G bases oriented on the same side
of the Pt−N4 plane, is preferentially
formed. Modeling studies suggest that this preference is due to
the presence of H bonds from the OH of the
bmic moiety toward the O6 of the G bases. The presence of many
conformers, present in solution, could also be
due to these H bonds. For the inactive complex
[Pt(bmi)Cl2] only one
GG-N7,N7 chelate is observed.
Differences
in reactivity toward G bases were also detected for the two platinum
complexes. The inactive bmi complex
proves to be the most reactive one, whereas the antitumor active bmic
compound is less reactive. Thus both
structural and kinetic properties may explain the different biological
properties of these new platinum compounds.